Evaluation of polygenic score for hypertrophic cardiomyopathy in the general population and across clinical settings

Sean L. Zheng, Sean J. Jurgens, Kathryn A. McGurk, Xiao Yun Xu, Chris Grace, Pantazis Theotokis, Rachel Buchan, Catherine Francis, Antonio de Marvao, Lara Curran, Wenjia Bai, Chee Jian Pua, Tang Hak Chiaw, Paloma Jordà, Marjon A. van Slegtenhorst, Judith M.a. Verhagen, Andrew R. Harper, Elizabeth Ormondroyd, Calvin Chin, Antonios Pantazis, John Baksi, Brian P. Halliday, Paul M. Matthews, Yigal M. Pinto, Roddy Walsh, Ahmad S. Amin, Marie‐José Goumans, Stuart A. Cook, Sanjay Prasad, Paul J.r. Barton, Declan P. O’Regan, R Thomas Lumbers, Anuj Goel, Rafik Tadros, Michelle Michels, Hugh Watkins, Connie R. Bezzina, James S. WaremedRxiv 2023 · DOI

Introduction

Hypertrophic Cardiomyopathy (HCM) is a leading cause of inherited cardiac morbidity and mortality, characterized by unexplained thickening of the left ventricular wall. Historically, HCM has been managed as a Mendelian "single-gene" disorder, with clinical attention focused on rare pathogenic variants in sarcomere genes. However, these variants are identified in only about 30% of cases, and even within families carrying the same mutation, disease severity and penetrance vary wildly.

Recent large-scale genome-wide association studies (GWAS) have revealed that common genetic variation—the cumulative effect of thousands of small-effect variants—contributes significantly to HCM risk. This study evaluates the clinical utility of a Polygenic Score (PGS) for HCM, demonstrating its power to modulate the risk of rare mutations, predict disease onset in families, and stratify the risk of death in diagnosed patients.

Methodology and Data Integration

To develop a robust predictive tool, the researchers derived a PGS using a multi-pronged approach:

  1. HCM GWAS: Utilizing data from the largest published HCM GWAS (5,900 cases).
  2. Multi-Trait Analysis (MTAG): To enhance statistical power, the authors incorporated genetically correlated traits from cardiac magnetic resonance imaging (MRI), specifically left ventricular wall thickness and volume, from over 36,000 UK Biobank participants.
  3. Bayesian Framework: The score was refined using PRS-CS to account for linkage disequilibrium across the genome.

The study validated this PGS across a diverse range of datasets, including the UK Biobank (UKB) for population-level analysis, the 100,000 Genomes Project (GeL) for rare disease cohorts, and specialized clinical datasets from the Erasmus Medical Centre and Royal Brompton & Harefield Hospitals. To address the historical bias toward European ancestries, the team also utilized a de novo GWAS from a Singaporean Chinese cohort to test cross-population performance.

Key Findings

1. Population-Wide Risk Stratification

In the general population (UK Biobank), the PGS proved to be a potent predictor of HCM. Individuals in the highest 1% of the PGS distribution faced a 14.5-fold increased risk of developing the condition compared to those with average scores. This suggests that common variation alone can drive disease risk to levels comparable to some rare mutations.

2. Modulating the Penetrance of Rare Mutations

One of the study's most significant insights is the "volume knob" effect of the PGS on rare, high-risk sarcomere mutations. Among carriers of these pathogenic variants, the likelihood of actually developing the disease (penetrance) was heavily influenced by their polygenic background:

  • High PGS Quintile: 17.2% penetrance.
  • Low PGS Quintile: 2.3% penetrance.

This nearly 10-fold difference explains why some family members with a "deadly" mutation remain asymptomatic while others suffer severe disease, providing a clearer framework for counseling mutation carriers.

3. Prognostic Value and Mortality

Beyond diagnosis, the PGS serves as a powerful prognostic tool. For patients already diagnosed with HCM, a high PGS was associated with significantly worse outcomes. Patients in the highest PGS quintile faced a 4-to-6-fold increase in the risk of death compared to those in the lowest quintile. The score also successfully stratified the risk of Major Adverse Cardiovascular Events (MACE), including heart failure and arrhythmias.

4. Clinical Utility in Family Screening

In the context of clinical genetics, the PGS effectively stratified the risk of disease progression in relatives of HCM patients. This capability could allow clinicians to tailor the frequency of cardiac screening—intensifying surveillance for high-PGS relatives while potentially reducing the burden on those at lower polygenic risk.

Limitations and Future Directions

Despite its promise, the study highlights the persistent "ancestry gap" in genomic medicine. The PGS, primarily derived from European data, showed diminished accuracy in African and South Asian populations. While the inclusion of a Singaporean Chinese cohort improved performance in East Asian groups, broader global representation in GWAS is essential for equitable clinical deployment.

Furthermore, while the retrospective data is compelling, prospective clinical trials are required to establish formal guidelines for integrating PGS into routine cardiology. Future work will likely focus on how these scores can be combined with imaging and clinical biomarkers to create a truly integrated model of personalized cardiovascular care.

Conclusion

This research marks a shift in how we perceive HCM—from a binary Mendelian trait to a complex interplay between rare and common genetic factors. By providing a tool that stratifies risk from the general population to the clinical bedside, this PGS offers a path toward more precise diagnosis, more accurate family counseling, and better-informed management of high-risk patients.

Summary updated

Abstract

Hypertrophic cardiomyopathy (HCM) is an important cause of morbidity and mortality, with rare pathogenic variants found in about a third of cases (sarcomere-positive). Large-scale genome-wide association studies (GWAS) demonstrate that common genetic variation contributes substantially to HCM risk. Here, we derive polygenic scores (PGS) from HCM GWAS, and multi-trait analysis of GWAS incorporating genetically-correlated traits, and test their performance in the UK Biobank, 100,000 Genomes Project, and across clinical cohorts. Higher PGS substantially increases population risk of HCM, particularly amongst sarcomere-positive carriers where HCM penetrance differs 10-fold between those in the highest and lowest PGS quintiles. In relatives of HCM patients, PGS stratifies risks of developing HCM and adverse outcomes. Finally, PGS strongly predicts risk of adverse outcomes in HCM, with a 4 to 6-fold increase in death between cases in the highest and lowest PGS quintiles. These findings promise broad clinical utility of PGS in the general population, in cases, and in families with HCM, enabling tailored screening and surveillance, and stratification of risk of adverse outcomes.
BibTeX
@misc{zheng2023evaluation,
  author = {Sean L. Zheng and Sean J. Jurgens and Kathryn A. McGurk and Xiao Yun Xu and Chris Grace and Pantazis Theotokis and Rachel Buchan and Catherine Francis and Antonio de Marvao and Lara Curran and Wenjia Bai and Chee Jian Pua and Tang Hak Chiaw and Paloma Jordà and Marjon A. van Slegtenhorst and Judith M.A. Verhagen and Andrew R. Harper and Elizabeth Ormondroyd and Calvin Chin and Antonios Pantazis and John Baksi and Brian P. Halliday and Paul M. Matthews and Yigal M. Pinto and Roddy Walsh and Ahmad S. Amin and Marie‐José Goumans and Stuart A. Cook and Sanjay Prasad and Paul J.R. Barton and Declan P. O’Regan and R Thomas Lumbers and Anuj Goel and Rafik Tadros and Michelle Michels and Hugh Watkins and Connie R. Bezzina and James S. Ware and James S Ware},
  title = {{Evaluation of polygenic score for hypertrophic cardiomyopathy in the general population and across clinical settings}},
  year = {2023},
  doi = {10.1101/2023.03.14.23286621},
  howpublished = {medRxiv},
}
Figure